Lightnews — Scholar-powered news

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · Jul 21

Thank you so much for this honor!

Volunteering with @ascocancer.bsky.social has been a big joy in my career and happy to continue many future years of service!

American Society of Clinical Oncology @ascocancer.bsky.social · Jul 21

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.

Learn more about FASCO distinction: brnw.ch/21wUiSd

1

Reposted by Dionisia Quiroga, DO, PhD, FASCO

American Society of Clinical Oncology @ascocancer.bsky.social · Jul 21

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.

Learn more about FASCO distinction: brnw.ch/21wUiSd

3 7

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Christine Hodgdon @christeeny513.bsky.social · May 31

Thanks to these wonderful running buddies @drgattimays.bsky.social & @quirogad.bsky.social & @oncoalert.bsky.social for making it all happen!!

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · May 31

@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social

1 5

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · May 31

Perfect #ASCO25 morning - beautiful Chicago lakeside run with two amazing leaders in breast cancer care and advocacy 🏃‍♀️🙏🏽 @christeeny513.bsky.social @drgattimays.bsky.social @oncoalert.bsky.social @ascocancer.bsky.social

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · May 31

@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social

1 4 10

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · May 23

See you next week at #ASCO25 !

@osucccjames.bsky.social @oncodaily.bsky.social

American Society of Clinical Oncology @ascocancer.bsky.social · May 23

Dr. Dionisia Quiroga shares her tips for making #ASCO25 a networking triumph for early-career oncology professionals: brnw.ch/21wSSRC

2

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · May 2

#ASCO25 is right around the corner!
✨With >40K registrants, how can you best stand out of the crowd and make meaningful connections during the conference?✨

Here are some tips for trainees & early-career oncologists:
connection.asco.org/do/networkin...
@ascocancer.bsky.social @ascopost.bsky.social

Networking at ASCO25: Strategies for Success

Dr. Dionisia Quiroga shares her tips for making the 2025 ASCO Annual Meeting a networking triumph for early-career oncology professionals.

connection.asco.org

1

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Christian Rolfo @christianrolfo.bsky.social · Apr 25

Today family picture with some of the 87 amazing faculty of our Division of Medical Oncology at The James CCC. Very honored to be part and lead this incredible team!
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social

4 6

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · Apr 23

Honored and grateful for the opportunity to discuss 3 oral abstracts at #ASCO25 and represent #OSUCCC @osucccjames.bsky.social @osuwexmed.bsky.social #Immunotherapy @sitcancer.bsky.social #PIIO @ascocancer.bsky.social

4 8

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Apr 21

Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social

Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...

www.gilead.com

4 9

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · Apr 16

My hometown 🙏🏽
Vaccinations work; please protect yourself and others

Dr. Zachary Rubin @rubinallergy.bsky.social · Apr 15

Measles case in Michigan reported. A baby may have exposed a lot of people recently.

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Christian Rolfo @christianrolfo.bsky.social · Apr 9

🚨We are hiring Medical Oncologists at @OhioStateMedOnc !

Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence

Send your applications

@OSUCCC_James @OhioStateMed

2 2

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Mark Cuban @mcuban.bsky.social · Mar 22

From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA

710 8.6K 32K

Reposted by Dionisia Quiroga, DO, PhD, FASCO

NPR @npr.org · Mar 21

Cancer researchers working on health disparities say President Trump's actions could hurt rural whites, who lag behind other groups in cancer screening.

Trump wants to erase DEI. Researchers worry it will upend work on health disparity

Cancer researchers working on health disparities say President Trump's actions could hurt rural whites, who lag behind other groups in cancer screening.

www.npr.org

30 100 470

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Mar 18

Deadline approaching! The #SITC Women in Cancer Immunotherapy Network Leadership Institute applications close March 24. Don’t miss your opportunity to participate in panel discussions and presentations from experienced female leaders. Learn more here: www.sitcancer.org/professional...

3 3

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Scott Delaney @scott-delaney.bsky.social · Feb 21

NIH indirects case update:

Hearing ongoing now, and I'll try to live tweet some notable exchanges.

Prior to more detailed arguments, Judge Kelley starts off with a few point questions to both sides:

(I'm paraphrasing here)

14 200 350

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Feb 12

Discuss real-world case studies with clinical experts! #SITC’s ACI: Women’s Malignancies program will explore practical insights to apply immunotherapy into clinical practice. Join Feb. 28 for a free CME program. Register now: ow.ly/bTFn50UYy9j
@drgattimays.bsky.social @veredstearns.bsky.social

3 3

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · Feb 8

In Ohio during FY23 (2022-2023) this was the impact of NIH funding:

$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported

This reduction in NIH indirect will decimate research and limit health care advances

www.unitedformedicalresearch.org/nih-in-your-...

NIH In Your State - United For Medical Research

Select a state on the map to see the impact of NIH funding across America.

www.unitedformedicalresearch.org

3 12

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Carl T. Bergstrom @carlbergstrom.com · Feb 8

1. Today the NIH director issued a new directive slashing overhead rates to 15%.

I want to provide some context on what that means and why it matters.

grants.nih.gov/grants/guide...

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD

grants.nih.gov

260 4.1K 7.1K

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · Feb 7

Great session with Dr Heather McArthur on treating early stage #TNBC #IO posted on #ReachMD @osuwexmed.bsky.social @osucccjames.bsky.social reachmd.com/programs/cme...

Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care

Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and ...

reachmd.com

1 2 6

Reposted by Dionisia Quiroga, DO, PhD, FASCO

OncoDaily @oncodaily.bsky.social · Feb 4

200 participants at OSU SABCS meeting - Christian Rolfo @christianrolfo.bsky.social
@stoverlab.bsky.social
@quirogad.bsky.social

oncodaily.com/blog/237555

#BreastCancer #Cancer #FightAgainstCancer #MedOnc #OncoDaily #Oncology #OSU #SABCSmeeting #Medicine #Health

Christian Rolfo: 200 participants at OSU SABCS meeting - OncoDaily

Christian Rolfo: 200 participants at OSU SABCS meeting / Breast Cancer, cancer, Christian Rolfo, Daniel Stover, Dionisia Quiroga, fight against cancer, Global

oncodaily.com

1 8

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Feb 3

Dr. Quiroga, we're delighted to have you on the expert panel and look forward to your presentation on immunotherapy for late-stage breast cancer!

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · Feb 2

📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!

A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Jan 29

#Immunotherapy for women’s malignancies continue to evolve. #SITC’s ACI: A Focus on Women’s Malignancies program provides clinicians with current updates in the use of IO to treat early/late-stage breast cancer. Join Feb. 28.

Register: www.sitcancer.org/education/ac...

#LearnACI #breastcancer

2 3

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · Feb 3

Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research

Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...

breast-cancer-research.biomedcentral.com

1 2 7

Reposted by Dionisia Quiroga, DO, PhD, FASCO

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · Feb 3

Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social

1 12 34

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · Feb 2

🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast

👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx

ascodaily.libsyn.com/advances-in-...

ASCO Daily News: Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations

Dr. Jessica Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive gen...

ascodaily.libsyn.com

3 5

Dionisia Quiroga, DO, PhD, FASCO @quirogad.bsky.social · Feb 2

📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!

A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Jan 29

#Immunotherapy for women’s malignancies continue to evolve. #SITC’s ACI: A Focus on Women’s Malignancies program provides clinicians with current updates in the use of IO to treat early/late-stage breast cancer. Join Feb. 28.

Register: www.sitcancer.org/education/ac...

#LearnACI #breastcancer

1 2